Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her 2 Positive Breast Cancer”

410 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 410 results

Large-scale testing (Phase 3)Study completedNCT00390455
What this trial is testing

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Who this might be right for
Estrogen Receptor PositiveHER2 Positive Breast CarcinomaHER2/Neu Negative+5 more
National Cancer Institute (NCI) 295
Testing effectiveness (Phase 2)UnknownNCT04034589
What this trial is testing

Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 46
Not applicableNot Yet RecruitingNCT07593196
What this trial is testing

HER2-positive Metastatic Breast Cancer in Kazakhstan

Who this might be right for
Metastatic Breast Cancer
AstraZeneca 240
Testing effectiveness (Phase 2)WithdrawnNCT00627627
What this trial is testing

Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer

Who this might be right for
Breast Cancer
MedImmune LLC 56
Testing effectiveness (Phase 2)Active Not RecruitingNCT06198751
What this trial is testing

Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 104
Large-scale testing (Phase 3)Ended earlyNCT06038539
What this trial is testing

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Who this might be right for
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
Biocon Biologics UK Ltd 55
Early research (Phase 1)Study completedNCT00068757
What this trial is testing

Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Who this might be right for
Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC 23
Testing effectiveness (Phase 2)Study completedNCT02654119
What this trial is testing

Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery

Who this might be right for
HER2 Positive Breast CarcinomaStage I Breast Cancer AJCC v7Stage IA Breast Cancer AJCC v7+4 more
University of Nebraska 20
Testing effectiveness (Phase 2)Study completedNCT01973660
What this trial is testing

PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 151
Large-scale testing (Phase 3)Study completedNCT01007942
What this trial is testing

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
HER2/Neu Over-expressing Locally Advanced Breast CancerMetastatic Breast Cancer
Novartis Pharmaceuticals 569
Not applicableStudy completedNCT05905939
What this trial is testing

HER2(Human Epidermal Growth Factor Receptor 2) -Positive Metastatic Breast Cancer in Russia

Who this might be right for
Breast Cancer
AstraZeneca 774
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07287098
What this trial is testing

Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

Who this might be right for
Breast Neoplasms
Eli Lilly and Company 600
Testing effectiveness (Phase 2)Study completedNCT00847171
What this trial is testing

Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 20
Post-approval studies (Phase 4)WithdrawnNCT03988114
What this trial is testing

Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company
Testing effectiveness (Phase 2)Looking for participantsNCT05035836
What this trial is testing

Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

Who this might be right for
Breast CancerHER2-positive
M.D. Anderson Cancer Center 20
Early research (Phase 1)Study completedNCT02060253
What this trial is testing

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

Who this might be right for
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+4 more
Memorial Sloan Kettering Cancer Center 9
Testing effectiveness (Phase 2)WithdrawnNCT02853071
What this trial is testing

Efficacy and Safety of Estracyt® in Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Centre Hospitalier Universitaire de Besancon
Not applicableUnknownNCT05188495
What this trial is testing

Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab

Who this might be right for
HER2-positive Metastatic Breast CancerPreviously Treated With TrastuzumabTrastuzumab Combined With Pertuzumab and Chemotherapy
Peking University Cancer Hospital & Institute 60
Not applicableLooking for participantsNCT06127979
What this trial is testing

Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 42
Large-scale testing (Phase 3)Active Not RecruitingNCT02115282
What this trial is testing

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Breast Adenocarcinoma+4 more
National Cancer Institute (NCI) 608
Load More Results